Stem cells in a cooler, being transported to the transplant unit where a patient will receive them.
Dana-Farber Cancer Institute, in partnership with Brigham and Women's
Hospital and Children's Hospital Boston, was one of only three large
stem cell transplant programs nationwide that consistently outperformed
the expected one-year survival rate for unrelated donor stem cell
transplants in the United States, according to an independent report
from the Center for International Blood & Marrow Transplant Research
The program had the highest one-year survival rate for the 14 centers
that performed more than 150 unrelated donor transplant cases between
January 2002 and December 2006, and the third highest survival rate for
the 26 centers that performed at least 100 unrelated donor transplants
cases during that same period.
"This rating reflects years of very hard work on the part of each member of our staff," said Joseph H. Antin, MD, chief of the Adult Stem Cell Transplantation Program
and medical director of the unrelated donor program at Dana-Farber and
Brigham and Women's. "All of the members of our program are committed to
both research and patient care. These two missions are inseparable.
Our research has measurably improved the lives of our patients and
resulted in the recognition of our program as a national leader."
oversees the Stem Cell Therapeutic Outcomes Database and each year
conducts a center-specific survival analysis of the transplant centers
in the U.S. that are affiliated with the National Marrow Donor Program.
The current report reviewed 8,847 unrelated donor transplant cases that
were conducted at 122 centers.
The overall one-year survival rate for all of the centers reviewed
was 53.9 percent. Dana-Farber, Brigham and Women's and Children's transplant program's
one-year survival rate was 67.1 percent, which was 19 percent higher
than the program's predicted survival rate (56.3 percent).
Unrelated donor stem cell transplants are used to treat an array of
diseases, including leukemias, lymphomas, myeloma, anemias, and many
other life-threatening blood, immune system, and genetic disorders.
Dana-Farber provides adult oncology care in partnership with
Dana-Farber/Brigham and Women's Cancer Center, a comprehensive service
that combines the expertise of Dana-Farber and Brigham and Women's
Hospital. Dana-Farber's extensive pediatric oncology services are
offered in conjunction with Children's Hospital Boston through
Dana-Farber/Children's Hospital Cancer Care.
Dana-Farber Cancer Institute (www.dana-farber.org)
is a principal teaching affiliate of the Harvard Medical School and is
among the leading cancer research and care centers in the United States.
It is a founding member of the Dana-Farber/Harvard Cancer Center
(DF/HCC), designated a comprehensive cancer center by the National
Cancer Institute. It is the top ranked cancer center in New England,
according to U.S. News & World Report,
and one of the largest recipients among independent hospital recipients
of National Cancer Institute and National Institutes of Health grant
Brigham and Women's Hospital (BWH) is a 777-bed nonprofit teaching
affiliate of Harvard Medical School and a founding member of Partners
HealthCare, an integrated health care delivery system. BWH is committed
to excellence in patient care with expertise in virtually every
specialty of medicine and surgery. For more information about BWH,
please visit www.brighamandwomens.org.
Children's Hospital Boston is home to the world's largest research
enterprise based at a pediatric medical center, where its discoveries
have benefited both children and adults since 1869. More than 500
scientists, including eight members of the National Academy of Sciences,
11 members of the Institute of Medicine and 12 members of the Howard
Hughes Medical Institute comprise Children's research community.
Founded as a 20-bed hospital for children, Children's Hospital Boston
today is a 397-bed comprehensive center for pediatric and adolescent
health care grounded in the values of excellence in patient care and
sensitivity to the complex needs and diversity of children and families.
Children's also is the primary pediatric teaching affiliate of Harvard
Medical School. For more information about the hospital and its research